Best Pharmaceutical Stocks To Research - October 16th

Key Points

• Three pharmaceutical stocks to watch include Praxis Precision Medicines, Recursion Pharmaceuticals, and Eli Lilly, which have recently had the highest dollar trading volume in the sector.
• Praxis Precision Medicines is focused on therapies for central nervous system disorders and is currently advancing multiple candidates in clinical trials, including an essential tremor treatment.
• Recursion Pharmaceuticals is innovating drug discovery through technology and has several candidates in various stages of clinical trials targeting conditions like neurofibromatosis and Clostridioides difficile infection.

Praxis Precision Medicines, Recursion Pharmaceuticals, and Eli Lilly and Company are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and market prescription drugs and related therapies. For investors, these equities are driven by factors such as clinical trial outcomes, regulatory approvals, patent protections, and drug pipelines, and they can carry higher volatility and regulatory and clinical-development risk than many other sectors. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Praxis Precision Medicines (PRAX)

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.

Read Our Latest Research Report on PRAX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Read Our Latest Research Report on RXRX

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read Our Latest Research Report on LLY